The deal, which includes Eli Lilly and Novo Nordisk, will slash prices for Medicare and Medicaid programme recipients.

White House’s landmark deal with Novo Nordisk and Eli Lilly will cut costs from at least $1,000 to about $350

The deal also means Medicare will start covering obesity drugs for some patients for the first time beginning next year.